Sun Pharma to complete Taro buyout after 17 years

Sun Pharma announces merger agreement with Israeli subsidiary, Taro Pharma. The Indian drugmaker will acquire outstanding shares of Taro Pharma for $348 million, resulting in full ownership. The merger is subject to closing conditions and upon completion, Taro will become a privately held company and its shares will no longer be listed on the NYSE.